2006, Number 2
PDF size: 128.69 Kb.
ABSTRACTBackground: Thalidomide is effective in several cutaneous diseases. The most important adverse event in patients with thalidomide treatment is peripheral neuropathy. This effect has been reported as irreversible and should be detected promptly. Diagnosis can be made considering the type and place where patients refer the pain. A medical examination and a proper interrogation are suggested, though definite diagnosis should be reached through a series of tests that include nerve conduction studies.
Objective: To determine the prevalence of peripheral neuropathy using nerve conduction studies in patients with thalidomide treatment at the Centro Dermatológico Pascua.
Patients and method: We made direct interviews and nerve conduction studies in 30 patients treated with thalidomide at the Centro Dermatológico Pascua.
Results: Prevalence of peripheral neuropathy was 13%, which is considered a high value, although the sample size was small.
Conclusions: It is necessary to identify the signs and symptoms of the peripheral neuropathy and to make nerve conduction studies in order to have an adequate control of the patients treated with thalidomide.
Chare TA, Finlay AY, Knight AG. Thalidomide usage in Wales: the need to follow guidelines. Br J Dermatol 2001;144:310-5.
Aitken G. La thalidomide dans les etats de reaction lepreux. Tesis Facultad de Medicina de París, 1968.
Casanova JM, Baradad M, Martí L. Talidomida, redescubrir un viejo fármaco. Piel 2004;5(6):297-309.
Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984;120:338-41.
Fullerton PM, O’Sullivan DJ. Thalidomide neuropathy: a clinical, electrophysiological and histological follow up study. J Neurol Neurosurg Psychiatry 1968;31:543-51.
Aronson IK, Yu R, West DP. Thalidomide-induce peripheral neuropathy. Arch Dermatol 1984;120:1466-70.
Lagueny A, Rommel A, Vignolly E. Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve 1986;9:837-44.
Tseng S, Pak G, Washenik K, Keitz M, Shupack J. Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996;35:969-79.
Hess CW, Hunziker T, Kuofer A. Thalidomide induced peripheral neuropathy: a prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986;223:83-89.
Bastuji-Garin S, Ochonoski S, Bouche P, Duguet C, Djerradine Z. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. Invest Dermatol 2002;119:1020-6.
Iris K, Aronson, Yu R, Dennis Pvan Der Broek H. Thalidomide-induce peripheral neuropathy. Arch Dermatol 1984;120:1466-70.
Radomsky C, Levine N. Thalidomide. Dermatol Clin 2001;19:87-102.
Hendler S, McCarty M. Thalidomide for autoimmune diseases. Med Hypotheses 1983;10:437-43.
Kimura J. Electrodiagnosis of nerve and muscle. 2nd ed. Philadelphia: FA Davis Company, 1989;pp:107-31.